Cargando…
Risk in CNS drug discovery: focus on treatment of Alzheimer's Disease
Despite rapid progress in our understanding of disease mechanisms and an exploding list of new targets for therapeutic intervention, drug discovery and development remains a highly risky business. Understanding the risk involved requires appreciation of the differing perspectives of risk held by the...
Autor principal: | Pritchard, J Fred |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2604886/ https://www.ncbi.nlm.nih.gov/pubmed/19090998 http://dx.doi.org/10.1186/1471-2202-9-S3-S1 |
Ejemplares similares
-
The Current Challenges for Drug Discovery in CNS Remyelination
por: Balestri, Sonia, et al.
Publicado: (2021) -
Approaches to CNS Drug Delivery with a Focus on Transporter-Mediated Transcytosis
por: Abdul Razzak, Rana, et al.
Publicado: (2019) -
Alzheimer’s Disease, Brain Injury, and C.N.S. Nanotherapy in Humans: Sonoporation Augmenting Drug Targeting
por: D’Arrigo, Joseph S.
Publicado: (2017) -
Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition
por: Papa, Alessandro, et al.
Publicado: (2022) -
Alzheimer’s Disease, Neuroprotection, and CNS Immunosenescence
por: Streit, Wolfgang J., et al.
Publicado: (2012)